Mette Deborah Hazenberg

Title: Mette Deborah Hazenberg: Innovator in AML Therapeutics

Introduction

Mette Deborah Hazenberg is a prominent inventor based in Amsterdam, Netherlands. She has made significant contributions to the field of medical research, particularly in the development of therapies for acute myeloid leukemia (AML). With a total of 3 patents, her work focuses on innovative solutions to combat hematological disorders.

Latest Patents

Hazenberg's latest patents include groundbreaking inventions aimed at addressing myeloproliferative and lymphoproliferative disorders. One of her notable inventions is titled "Means and methods for counteracting myeloproliferative or lymphoproliferative disorders." This invention provides human AML-specific binding compounds that can effectively bind to a cell surface component of AML cells. Additionally, she has developed therapeutic uses for these binding compounds against AML. Another significant patent is "AML antigens and uses thereof," which presents novel compounds comprising an antigen of AML cells and their various applications.

Career Highlights

Throughout her career, Mette has worked with several esteemed companies, including Kling Biotherapeutics B.V. and Aimm Therapeutics B.V. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative therapies.

Collaborations

Mette has collaborated with notable professionals in her field, including Hergen Spits and Marijn Aletta Gillissen. These partnerships have enriched her research and expanded the impact of her inventions.

Conclusion

Mette Deborah Hazenberg is a trailblazer in the field of AML therapeutics, with a focus on innovative solutions that address critical medical challenges. Her contributions through her patents and collaborations highlight her commitment to advancing healthcare.